Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Small Cell Lung Cancer
DRUG: Durvalumab|DRUG: Tremelimumab|OTHER: Placebo
Progression-free survival (PFS), To assess the efficacy of Durvalumab monotherapy vs Placebo in terms of PFS, Approximately 6 years|Overall Survival (OS), To assess the efficacy of Durvalumab monotherapy vs Placebo in terms of OS, Approximately 6 years
Overall Survival (OS), To assess the efficacy of Durvalumab \& Tremelimumab combination therapy vs Placebo in terms of OS, Approximately 6 years|Objective Response Rate (ORR), Approximately 6 years|Progression-free survival PFS, To assess the efficacy of durvalumab and tremelimumab combination therapy compared to placebo in terms of PFS, Approximately 6 years|Progression-free survival at 18 months (PFS18), Approximately 6 years|Progression-free survival at 24 months (PFS24), Approximately 6 years|Time to death or distant metastasis (TTDM), Approximately 6 years|Proportion of patients alive at 24 months (OS24), Approximately 6 years|Proportion of patients alive at and 36 months (OS36), Approximately 6 years|Time from randomization to second progression (PFS2), Approximately 6 years|To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-C30 v3, Approximately 6 years|To assess the PK of durvalumab and tremelimumab in blood (peak trough concentration), Approximately 6 years|Presence of anti-drug antibodies (ADA) for durvalumab and tremelimumab (confirmatory results: positive or negative), Approximately 6 years|PD-L1 expression in tumor and/or immune cells relative to response/efficacy outcomes (PFS, OS & ORR)., To investigate the relationship between PDL1 expression \& spatial distribution with Durva (mono) therapy \& Durva+Treme (combination) therapy, Approximately 6 years|To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-LC13, Approximately 6 years
Adverse Events, Approximately 6 years
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy